达拉非尼联合曲美替尼双靶治疗相关眼毒性研究进展  

Research progress in ocular toxicities associated with dual target therapy of dabrafenib and trametinib

作　　者：黄硕涵 王萌萌 叶璇 郭子寒 单瀚 翟青 刘继勇 杜琼 Huang Shuohan;Wang Mengmeng;Ye Xuan;Guo Zihan;Shan Han;Zhai Qing;Liu Jiyong;Du Qiong(Department of Pharmacy,Fudan University Shanghai Cancer Center,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院药剂科,上海200032

出　　处：《药物不良反应杂志》2023年第5期308-314,共7页Adverse Drug Reactions Journal

基　　金：上海市卫生健康委员会“医苑新星”青年医学人才培养资助计划(沪卫人事[2020]87号)。

摘　　要：达拉非尼联合曲美替尼(DabTram)双靶治疗在多种恶性肿瘤的治疗中起重要作用。眼毒性是DabTram治疗中相对不常见但可能产生严重后果的不良反应。目前针对DabTram引起的眼毒性缺乏系统性研究,导致临床对DabTram相关眼毒性认识不足。本文对DabTram相关眼毒性的文献进行系统性回顾,对其发生情况、临床特征、发生机制及治疗措施等进行综述,并提出相应的临床用药管理策略,为临床安全用药提供参考。Dual target therapy of dabrafenib combined with trametinib(DabTram)plays an important role in the treatment of malignancies.Ocular toxicities are adverse reactions which are relatively uncommon but potentially serious in DabTram treatment.At present,there is a lack of systematic research on ocular toxicities caused by DabTram,leading to insufficient understanding of this problem.In this paper,the literature on DabTram-related ocular toxicities are systematically reviewed,especially focusing on the incidence,clinical characteristics,mechanisms of occurrence,therapeutic measures and so on,and the corresponding management pathways in clinical medication were proposed to provide references for safe use of DabTram in clinic.

关 键 词：眼疾病 眼损伤 葡萄膜炎 视网膜疾病 达拉非尼 曲美替尼 

分 类 号：R969.3[医药卫生—药理学]